{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.356","value":"16.04"}]}],"title":"Pre-dose (Cmin) (n:22)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.954","value":"46.50"}]}],"title":"2 hours post-dose (C2h) (n:24)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"description":"Characterize the pharmacokinetics (PK) of everolimus in combination with exemestane using Cmin (pre-dose) and C2h (post-dose) at week 4 in a small group of patients.","dispersionType":"Standard Deviation","groups":[{"description":"Everolimus 10 mg daily in combination with exemestane 25 mg daily","id":"OG000","title":"Everolimus + Exemestane"}],"paramType":"MEAN","populationDescription":"Safety Set population consisted of all patients who received at least one dose of study treatment and who had at least one valid post-baseline safety assessment. Although the safety set was considered for the analysis (N), only participants (n) who had pre-dose \\& 2 hours post-dose values for the given time points were analyzed for that time point.","reportingStatus":"POSTED","timeFrame":"pre-dose, 2 hours post-dose","title":"Everolimus Concentrations at Week 4","type":"SECONDARY","unitOfMeasure":"ng/mL"}